Integrative Approaches to Managing Irritable Bowel Syndrome (IBS)

The purpose of this project is to examine whether a low cost, group-oriented integrative medicine approach to irritable bowel syndrome improves participant outcomes. The intervention will combine nutrition counseling on the low FODMAP diet (decreased grains and other disaccharides) and mind-body training with follow-up health coaching.

These participants will be randomized to either a 4-week group-oriented treatment intervention incorporating a low FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides and polyols) diet and mind-body therapies followed by an 8-week health coaching follow-up period or a waitlist control group. At the end of the 12-week study period, waitlist subjects will be offered the four-week nutrition and mind-body intervention. Over the 12-week study period, we will examine and report on the impact of this treatment intervention on IBS symptoms and quality of life in this population. The investigators will collect data on IBS outcomes as well as on depression and stress.

Study Overview

• Status: Completed
• Conditions: Irritable Bowel Syndrome; IBS
• Intervention / Treatment: Behavioral: Nutrition/Mind-Body Coaching

Detailed Description

This project will test the effectiveness of an integrative medicine approach in treating irritable bowel syndrome (IBS). Over the course of 18 months, we will recruit 85 participants with IBS in New York City. These participants will be randomized to either a 4-week group-oriented treatment intervention incorporating a low FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides and polyols) diet and mind-body therapies followed by an 8-week health coaching follow-up period or a waitlist control group. At the end of the 12-week study period, waitlist subjects will be offered the four-week nutrition and mind-body intervention. Over the 12-week study period, we will examine and report on the impact of this treatment intervention on IBS symptoms and quality of life in this population. The investigators will collect data on IBS outcomes as well as on depression and stress.

The hypothesis is that participants will report decreased symptoms and improved function and quality of life as a result of the four-week nutrition and mind-body intervention and 8-week health coaching follow-up period. The goal of this project is to develop a low-cost, effective integrative intervention for IBS, which can be replicated in settings across the U.S.

Objectives The purpose of this project is to examine whether a low cost, group-oriented integrative medicine approach to irritable bowel syndrome improves participant outcomes. The intervention will combine nutrition counseling on the low FODMAP diet and mind-body training with follow-up health coaching.

The hypothesis is that participants will report decreased symptoms as measured by the IBS Symptom Severity Score and improved function and quality of life as a result of the intervention when compared to usual care.

Background Irritable bowel syndrome (IBS) is a chronic debilitating functional gastrointestinal disorder that has a profound effect on the quality of life (QOL) of individuals with IBS. The estimated prevalence of IBS in the general population ranges from 3% to 20%, with most studies estimating that IBS affects 10% to 15% of the general population. Despite its high level of prevalence, the exact causes of IBS are not well understood. Researchers believe that IBS is caused by a wide variety of mental and physical health problems including hypersensitivity, brain-gut signal issues, bacterial gastroenteritis, depression, anxiety, food sensitivity, body chemical imbalances, and/or genetics.

Background: Low FODMAP Diet for IBS More than 60% of IBS patients report worsening of symptoms after meals, 28% of these within 15 minutes after eating and 93% within 3 hours. The role of diet in inducing or exacerbating IBS systems has been explored for decades. Numerous studies have examined the role of lactose intolerance and fructose malabsorption in IBS. Additional research on oligosaccharides and the incompletely absorbed sugar alcohol polyols, sorbitol, and mannitol, has revealed a role in IBS symptoms. Grouping of these poorly absorbed, short chain carbohydrates- fermentable oligosaccharides, disaccharides, monosaccharides and polyols- according to their chain length resulted in the acronym FODMAP, and in 2005, the first paper describing the FODMAP hypothesis was published. Evidence continues to accumulate that the consumption of FODMAPs may contribute to symptoms in individuals with IBS.

FODMAPs are poorly absorbed, osmotically active, and increase delivery of water and fermentable substrates to the proximal colon and are rapidly fermented by bacteria. The poor absorption and fermentation of the short chain carbohydrates contributes to the bloating, distension, abdominal pain, and flatulence of individuals with IBS. In a comparison of standard dietary advice versus FODMAP for individuals with IBS, a low FODMAP diet showed significantly greater reduction in abdominal pain, bloating, and flatulence compared to the standard dietary advice group. A high FODMAP diet altered the pattern of gas production, induced prolonged hydrogen production in the intestine that was greater in individuals with IBS versus healthy controls, influenced the amount of methane produced, and induced gastrointestinal and systemic symptoms in individuals with IBS. A low FODMAP diet reduced abdominal pain, bloating, flatulence, and diarrhea in individuals with inflammatory bowel disease. In a prospective study of 90 patients with IBS followed for 15 months, a low FODMAP diet significantly decreased abdominal pain, bloating, flatulence, and diarrhea, with greater improvement with greater dietary adherence.

Background: Mind-Body Therapies for IBS Psychological therapies or mind-body therapies such as hypnosis, biofeedback, and psychotherapy represent some of the most effective treatments for IBS and are especially useful for motivated patients with moderate to severe IBS.

The scientific evidence involving mind-body therapies for IBS began in 1927 when American researcher, Dr. Edmund Jacobson, conducted the first randomized trial using progressive relaxation for IBS treatment and found significant benefit. In recent years, a vast majority of research surrounding mind-body approaches for IBS has come from a research group at University Hospital in South Manchester, UK led by Dr. Peter Whorwell. In 1984, the Whorwell group developed a hypnosis procedure specifically for treating IBS called "gut directed hypnotherapy". The intervention consists of seven half-hour sessions of decreasing frequency. In addition, patients are all given self-hypnosis tapes for daily practice. A 2005 review published by the American Society of Clinical Hypnosis examined 14 studies measuring efficacy and mechanism of hypnosis for IBS treatment (12 of the 14 studies utilized an adaptation of the Whorwell group procedure). Based on the studies investigated, the review concluded "hypnosis consistently produces significant results and improves the cardinal symptoms of IBS in the majority of patients." A separate 2006 review conducted by researchers at the University of Birmingham in England, concluded that existing scientific evidence suggest that hypnosis is effective in the treatment and management of IBS (10 of the 18 studies examined indicated significant benefit).

Regarding long-term benefit, the existing scientific evidence is supportive of mind-body approaches for IBS treatment. A long-term follow-up study of IBS patients (n=204) treated with hypnosis revealed that of the 71% who initially responded to hypnosis, 81% maintained their improvement overtime while the remaining 19% reported only slight deterioration in their IBS symptoms. Also important was that patients reported to be using fewer medications to manage IBS following hypnosis treatment. In their conclusion, the study authors determined that the benefits of hypnosis seemed to last for up to 5 years after treatment. A 1989 comparative study from England determined that hypnosis for treatment of IBS in groups of up to 8 patients was as effective as individual therapy.

• Study Type: Interventional
• Enrollment (Actual): 52
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • New York
    • New York, New York, United States, 10016
      • Center for Health and Healing

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• IBS diagnosis> 12 months in duration
• Over 18 years of age
• English speaking

Exclusion Criteria:

• Active major psychiatric illness which would potentially interfere with participation in the study 2. Pregnancy 3. Active eating disorder

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Nutrition/Mind-Body Coaching; The intervention will consist of weekly group sessions lasting 75-90 minutes during which participants will receive training in the FODMAP diet and mind-body skills.	Behavioral: Nutrition/Mind-Body Coaching; Following the four-week treatment intervention, participants will then be enrolled in an 8-week health coaching follow-up period. During this time participants will have a 45-60 minute telephone session with a health coach weekly for two weeks, then biweekly for four weeks.
No Intervention: Waitlist Control Group; Waitlist subjects. At the end of the 12-week study period, waitlist subjects will be offered the four-week nutrition and mind-body intervention.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
IBS Symptom Severity Scale	a validated tool which is currently the gold standard for evaluating interventions for IBS. Change in IBS Symptom Severity Scale at week 12 as compared to Baseline	Baseline and week 12
IBS Quality of Life (IBS-QOL)	Change in IBS-QOL at week 12 as compared to Baseline	Baseline and Week 12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Patient Global Impression of Change (PGIC)	The PGIC is a single question 7-point categorical scale that captures a patient's experience of treatment. Change in PGIC at week 12 as compared to baseline.	Baseline and Week 12
Perceived Stress Scale (PSS)	Change in Measure of Stress at week 12 as compared to baseline	Baseline and Week 12

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Center for Epidemiological Studies - Depression Scale (CES-D)	Change in a well-validated, 20-item measure of depression at week 12 compared to baseline	Baseline and Week 12

Collaborators and Investigators

• Sponsor: Beth Israel Medical Center
• Investigators: Principal Investigator: Elizabeth McDonald, MS,RD,CSS, The Center for Health & HealingDepartment of Integrative MedicineMount Sinai Beth Israel

Publications and helpful links

General Publications

• 1Chey, W D, Olden, K, et al.2002Utility of the Rome I and Rome II criteria for IBS in U S women. Am J Gastro 97(11), 2803-2811 2 Grundmann O, Yoon SL. IBS: epidemiology, diagnosis, and treatment: an update for health-care practitioners Jl of Gastro and Hep 2010;25:691-699. 3

Study record dates

Study Major Dates

• Study Start: April 1, 2015
• Primary Completion (Actual): June 28, 2017
• Study Completion (Actual): June 28, 2017

Study Registration Dates

• First Submitted: April 28, 2015
• First Submitted That Met QC Criteria: May 4, 2015
• First Posted (Estimate): May 7, 2015

Study Record Updates

• Last Update Posted (Actual): February 14, 2018
• Last Update Submitted That Met QC Criteria: February 12, 2018
• Last Verified: February 1, 2018

More Information

Terms related to this study

• Keywords: Irritable Bowel Syndrome; IBS; Integrative Medicine; FODMAP; Mind-Body Training
• Additional Relevant MeSH Terms: Digestive System Diseases; Pathologic Processes; Disease; Gastrointestinal Diseases; Colonic Diseases, Functional; Colonic Diseases; Intestinal Diseases; Syndrome; Irritable Bowel Syndrome
• Other Study ID Numbers: 010-15